Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis

Dalziel K, Round A, Stein K, Garside R, Price A
Record ID 32004000651
English
Authors' objectives:

This assessment evaluates the effectiveness of imatinib as first-line treatment for those with chronic myeloid leukaemia (CML) in chronic phase compared with interferon-alpha (IFN-a), hydroxyurea and bone marrow transplantation (BMT), and the cost-effectiveness of imatinib compared with IFN-a and hydroxyurea.

Authors' recommendations: Imatinib appears to be more effective than current standard drug treatments in terms of cytogenetic response and progression-free survival, with fewer side-effects. However, there is uncertainty concerning longer term outcomes, the development of resistance to imatinib, the duration of response and the place of imatinib relative to BMT. New issues are continually arising, such as optimal management pathways and combination therapies.
Authors' methods: Systematic review, Economic evaluation
Details
Project Status: Completed
URL for project: http://www.hta.ac.uk/1343
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antineoplastic Agents
  • Bone Marrow Transplantation
  • Costs and Cost Analysis
  • Hydroxyurea
  • Interferons
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.